Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today ...
Jefferies analysts identified their preferred mid-cap biotechnology stocks ahead of third-quarter earnings, with Oncorus (ONC) emerging as their top commercial pick, followed by Revolution Medicines ...
Free ArticleFrom the Japanese and US markets on October 16, 2026, we highlight three stocks for which we could confirm the ...
Stocks futures were mixed on Friday, with the S&P 500 and Nasdaq on track for weekly losses, capping a volatile week.
Beijing proposes controls on five biomedical technologies but exempts licensing, partnerships and contract research, keeping ...
Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already ...
BEIJING, Oct 16 (Reuters) - China has proposed adding 40 technologies across the artificial intelligence, biomedicine and ...
The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.
BioTissue Holdings Inc., a biotechnology company specializing in regenerative tissue products for ocular health, has been ...
A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...
Parker Institute Investigators’ Startups Azalea and Medici Named to 2026 Endpoints 11 / Azalea Therapeutics, Biotechnology, ...
A narrative review highlights the efficacy and safety of lifitegrast for reducing ocular surface inflammation in dry eye disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results